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ABSTRACT
Objective To evaluate the efficacy of a short course of
parent initiated oral prednisolone for acute asthma in
children of school age.
Design Double blind, randomised, placebo controlled,
crossover trial in which episodes of asthma, rather than
participants, were randomised to treatment.
Setting The Barwon region of Victoria, Australia.
Participants Children aged 5-12 years with a history of
recurrent episodes of acute asthma.
Intervention A short course of parent initiated treatment
with prednisolone (1 mg/kg a day) or placebo.
Main outcome measures The primary outcome measure
was the mean daytime symptom score over seven days.
Secondary outcome measures were mean night time
symptom score over seven days, use of health resources,
and school absenteeism.
Results 230 children were enrolled in the study. Over a
three year period, 131 (57%) of the participants
contributedatotalof308episodesofasthmathatrequired
parent initiated treatment: 155 episodes were treated with
parent initiated prednisolone and 153 with placebo. The
mean daytime symptom score was 15% lower in episodes
treated with prednisolone than in those treated with
placebo (geometric mean ratio 0.85, 95% CI 0.74 to 0.98;
P=0.023). Treatment with prednisolone was also
associatedwitha16%reductioninthenighttimesymptom
score (geometric mean ratio 0.84, 95% CI 0.70 to 1.00;
P=0.050),areducedrisk of health resourceuse(oddsratio
0.54, 95% CI 0.34 to 0.86; P=0.010), and reduced school
absenteeism (mean difference −0.4days,95%CI −0.8to0.
0d a y s ;P =0.045).
Conclusion A short course of oral prednisolone initiated
by parents when their child experiences an episode of
acute asthma may reduce asthma symptoms, health
resource use, and school absenteeism. However, the
modestbenefitsofthisstrategymustbebalancedagainst
potential side effects of repeated short courses of an oral
corticosteroid.
Trial registration ISRCTN 26232583.
INTRODUCTION
Acute asthma is one of the leading causes of emer-
gency department presentation and hospital admis-
sion worldwide.
1 Strategies to reduce the burden of
symptoms related to acute asthma and cut health
resource use are clearly needed. There is high level
evidence that oral corticosteroids are effective in the
treatment of acute asthma in children of school age
when administered after the child has been assessed
by a doctor.
2
Manyofthebenefitsoforalcorticosteroidshavebeen
shown to begin within three hours of administration,
3
and delayed dosing is less effective at resolving acute
asthma.
4Incorporatingparentinitiationoforalcorticos-
teroids into the education and action plans for acute
asthmathatdoctorsprovidefamiliesmaybeaneffective
way to ensure oral corticosteroid therapy is initiated
promptly when a child suffers an episode of acute
asthma.However,astrategyofparentinitiatedoralcor-
ticosteroids is likely to result in higher levels of admin-
istrationofcorticosteroidstochildrenwithasthma.This
issue is of concern because in addition to their immedi-
ateeffectsonbehaviour
5andadrenalfunction,
6oralcor-
ticosteroids are linked with reduced adult height in
children with asthma.
7 For example, as few as five
short courses of oral corticosteroids over a seven year
period during childhood has been associated with
diminished bone mineral accrual.
8 Therefore, the
potentialbenefitsofparentinitiatedoralcorticosteroids
require careful evaluation.
Parent initiated treatment with oral corticosteroids
seems to be ineffective among preschool children with
so called “viral induced wheeze,”
9 and the European
Respiratory Society recently advised against parent
initiated oral corticosteroids in children of preschool
age with recurrent wheeze.
10 Existing evidence regard-
ing parent initiated oral corticosteroids in school age
children with asthma is inadequate,
11 and the role of
parent initiation of oral corticosteroids is not clarified
in international asthma management guidelines.
1213
None the less, parent initiated oral corticosteroids are
widely used in clinical practice.
14
We undertook a double blind, randomised, cross-
over trial to determine the effectiveness of parent
initiated oral prednisolone compared with placebo in
children of primary school age who experience recur-
rent episodes of acute asthma.
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Patients
This single centre population based study was con-
ducted in the Barwon region of Victoria, Australia.
Children aged 5 to 12 years who had experienced
four or more episodes of acute asthma requiring at
least24hoursofbronchodilatortherapyinthepreced-
ing12monthswereeligibletoparticipate,regardlessof
the presence or absence of asthma interval symptoms.
Wejudgedthatthesecriteriacouldbeappliedinagen-
eral practice setting and would identify children likely
to have further episodes of acute asthma.
Weconductedasurveyamongparentstodetermine
the prevalence of asthma symptoms in children at pri-
mary school in the Barwon region and included a
request for respondents to volunteer their contact
details.
15 Parents who reported that their child had
experienced four or more episodes of wheeze during
the preceding 12 months were contacted and under-
went a structured telephone interview designed to
identify children likely to meet the trial eligibility cri-
teria. We also identified potential participants via the
Geelong Hospital. Potential participants then under-
went an assessment with a single paediatrician (PJV)
to determine eligibility.
Procedures
We randomised episodes of acute asthma, rather than
participants. Participants were randomly assigned to
one of four sequences of study medication (ABAB,
ABBA, BAAB, or BABA, where A=prednisolone and
B=placebo).Eachdiscreteepisodeofacuteasthmawas
treated with one or the other of the parent initiated
study medications (A or B) in the sequence specified.
Participants were able to contribute a maximum of
eight episodes of acute asthma to data collection.
The hospital pharmacist stored the sequence codes
and dispensed the study medication for the first epi-
sode at the time of enrolment and subsequent medica-
tions after each episode according to the assigned
sequence. The prednisolone solution we used was
Redipred(AspenPharmacarePtyLtd;SaintLeonards,
NSW, Australia), which contains 6.72 mg/ml of the
active ingredient, prednisolone sodium phosphate.
The placebo solution was also manufactured by the
makersof Redipred;however,the hospitalpharmacist
added 0.1% quinine bisulphate to the placebo mixture
tomimicthebittertasteofprednisolone.Thebottlesof
prednisoloneandplaceboappearedidentical.Weused
a once daily dose of 1 mg per kg in dosing intervals of
10 mg (that is, 10, 20, 30, 40, or 50 mg). Any doctor
could substitute the study medication with an oral cor-
ticosteroid if they deemed it appropriate because of
worsening or persisting symptoms. Children in the
study were given parent initiated prednisolone or pla-
cebo in addition to their standard treatment.
Episodesofacuteasthmaweredefinedbythefollow-
ing advice given to parents: “If from previous experi-
ence you suspect this is a more severe attack, or if the
symptoms are not getting better in about 6 to 8 hours
withregularuseofrelievermedication,giveyourchild
the study medication immediately.” Parents were
instructed to continue to administer the study medica-
tionforthreetofivedaysdependingonthepersistence
or resolution of their child’s asthma symptoms. To
ensure an adequate washout period and that the epi-
sodes were discrete, parents were instructed not to
commence a course of study medicine until a mini-
mum of 14 days after starting the previous treatment
and seven days after stopping a previous course of
study medication or oral corticosteroids. Parents were
instructed not to increase the dose of inhaled corticos-
teroid (if applicable) during an exacerbation.
During the enrolment process, a personalised
asthmamanagementplan wasdevelopedfor each par-
ticipant in accordance with the local asthma manage-
ment guidelines.
16 We sought to ensure that the use or
non-use of any additional asthma preventive medica-
tions was appropriate, that an appropriate drug deliv-
ery device was being used effectively, that there was a
sound understanding of dosing (including the fact that
for children older than 6 years it was appropriate to
deliver up to 12 actuations (1200 μg) of salbutamol at
atime),andthatthefamiliesunderstoodthecriteriafor
seeking a medical review. Parents were instructed to
seekamedicalreview:(1)iftheirchildhadabadattack
or they were worried; (2) if their child needed salbuta-
mol more than every 3 hours; (3) if their child was get-
ting little or no relief from salbutamol; or (4) if
wheezing lasted more than 24 hours and was not get-
ting better.
The participant’s atopic status was determined via
skin prick testing in accordance with standard
guidelines.
17 The physician conducting enrolment
(PJV) recorded a subjective impression of the parent’s
competence with asthma management on a five point
scale. Adherence was determined by correlating the
parent’s report with the amount of study medication
remaining when data collection was complete.
The primary outcome measure was mean daytime
symptom score over seven days according to the pae-
diatricasthmadiary
18(table 1).Thisdaytimesymptom
score was chosen because it is a well validated instru-
ment for measuring a child’s experience of acute
asthma. Secondary outcome measures were the mean
night time symptom score, health resource use,
asthma-free days (daytime symptom score of zero),
days of school missed,days of work missed by the par-
ent(s),andsubstitutionofthestudymedicationwithan
oral corticosteroid following a medical review. Health
resource use was a dichotomous outcome defined by
the occurrence of a local doctor, paediatrician, or
emergencydepartmentreviewforacuteasthmaduring
the seven days after initiation of the study medication.
Symptomscores,healthresourceuse,andbehavioural
changes were documented in the diaries.
Statistical analysis
We conducted a log scale sample size calculation
19 to
determine how many episodes of acute asthma would
berequiredtodetecta20%reductioninthemeanday-
time symptom score, basing the anticipated mean and
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publications
18 and using an alpha value of 0.05 with a
power value of 0.9. This calculation indicated that we
would require 154 episodes of acute asthma per treat-
ment group to ensure the study would be sufficiently
powered. The trial statistician (JBC) conducted a pre-
planned and blinded interim analysis when data on
160 episodes of acute asthma had been collected. The
differencebetweentreatmentgroupsindaytimesymp-
tom score and health resource use was insufficient to
meet the Haybittle-Peto stopping rule.
20
All episodes of acute asthmathat resulted in the par-
ticipantreceivingatleastonedoseofthestudymedica-
tion were included in the analyses for health resource
use. For each of the diary derived outcomes, however,
weincludedonlydiariesinwhichalltheitemsrelevant
to the calculation of the given outcome were com-
pleted. The daytime symptom score and night time
symptomscorewere analysedin alog scale,withcom-
parisons reported as geometric mean ratios. Analyses
were performed using generalised estimating equa-
tions to allow forcorrelation amongrepeated observa-
tions collected from participants contributing multiple
episodes of acute asthma.
21 Dichotomous outcomes
such as health resource use were compared between
treatmentarms,withoddsratiosobtainedfromlogistic
regression models fitted using the generalised estimat-
ing equations method. Analyses were performed with
Stata, version 10 (Stata Corporation; Austin, TX).
RESULTS
Two hundred and five children were identified via the
asthma survey and were enrolled between 8 March
and 18 September 2005. A further 25 eligible partici-
pants were identified by presentation to the Geelong
Hospital during the course of the trial. The recruit-
ment, randomisation, and follow-up of participants
are shown in figure 1.
Approximately 340 children in the Barwon region
would have met the study eligibility criteria. Thus, we
estimate that the 230 children who participated in the
study represented greater than 60% of those who were
eligible in the region. Of the 230 children who were
randomly assigned treatment, 225 (98%) stayed in the
study until data collection was completed. The mean
period for which participants were eligible to contri-
bute episodes was 2 years and 9 months.
Between 14 March 2005 and 24 May 2008, 131
(57%) of the 230 participants contributed a total of
308 episodes of asthma that required parent initiated
treatment with the study medication. The baseline
characteristics of the 131 participants who contributed
episodes are shown in table 2. At the time of enrol-
ment, almost half (56/131 (43%)) of the participants
who contributed episodes reported asthma interval
symptoms (more than one disturbed night per week;
difficultyparticipatinginphysicalactivities;orbronch-
odilator use on more than one day per week). Two
thirds (89/131 (68%)) had been prescribed an asthma
preventive medication for regular use, in accordance
with current asthma management guidelines.
Thenumbersofepisodescontributedperparticipant
were as follows: 55 participants contributed one epi-
sode; 29 contributed two; 23 contributed three; nine
contributed four; eight contributed five; one contribu-
ted six; four contributed seven; and two contributed
eight. Only seven participants contributed more than
two episodes a year. All the daytime symptom score
items in the symptom diary were completed for 140
(90%) of the 155 episodes treated with prednisolone
and 136 (89%) of the 153 of the episodes treated with
placebo. Complete data on health resource use were
available for all 308 episodes. As a result of the trial’s
crossover design, the baseline characteristics of the
participants were similarly distributed between epi-
sodes treated with prednisolone and those treated
with placebo.
Outcomes
The differences between episodes treated with predni-
soloneandthosetreatedwithplaceboinasthmasymp-
tom scores, asthma-free days, and missed days of
school and work are summarised in table 3. The day-
timesymptomscorewas15%lowerinepisodestreated
Table 1 |Daytime and night time symptom score diary
18
Daytime Please fill this out before going to bed
How much of the time did you have
trouble breathing today?
None of the time A little of the time Some of the time A good bit of the time Most of the time All of the time
Circle one number 0 1 2 3 4 5
How much did your asthma bother
you today?
Did not bother me Bothered me a little Bothered me
somewhat
Bothered me a good
deal
Botheredmeverymuch Botheredmeasmuchas
possible
Circle one number 0 1 2 3 4 5
How much of the time did your
asthma limit your activity today?
None of the time A little of the time Some of the time A good bit of the time Most of the time All of the time
Circle one number 0 1 2 3 4 5
Night time Please fill this out in the morning
Were you woken by asthma? (either
during the night or in the morning)
No Once More than once Awake all night
Circle one number 0 1 2 3
The daytime symptom score was calculated by adding the circled response (0 to 5) for each of the three daytime questions (total 15). A mean score was derived over a seven day period.
The night time symptom score was calculated from the response (0 to 3) to the single night time question. A mean score was derived over a seven night period.
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with placebo (geometric mean ratio 0.85, 95% CI 0.74
to 0.98; P=0.023). A similar reduction was seen in the
night time symptom score, but the statistical evidence
was slightly weaker (geometric mean ratio 0.84, 95%
CI0.70to1.00;P=0.05).Therewaslittleevidencefora
difference between treatment groups in the number of
asthma-free days (mean difference 0.3 days, 95% CI
−0.1 to 0.6 days; P=0.124). Children missed fewer
days of school for episodes treated with prednisolone
than for those treated with placebo (mean difference
−0.4 days, 95% CI −0.8 to 0.0 days; P=0.045), but
there was no difference in the amount of work missed
by parents (mean difference −0.1 days, 95% CI −0.4 to
0.3 days; P=0.765). There was no evidence that the
effect of prednisolone compared with placebo on day-
time symptom score and health resource use was
greater in any particular subgroup (fig 2).
The rates of asthma related health resource use and
substitution of the study medication with an oral corti-
costeroidaresummarisedintable 4.Episodesofasthma
treatedwithprednisolonewerelesslikelytoresultinuse
of health resources than episodes treated with placebo
(odds ratio 0.54, 95% CI 0.34 to 0.86; P=0.010). The
majority of this difference was owing to a reduced rate
of local doctor review for episodes treated with predni-
solone. There was also some evidence that treatment
with prednisolone was associated with a reduced risk
of hospital admission (odds ratio 0.41, 95% CI 0.16 to
1.05; P=0.064), but the estimated number of episodes
needed to treat was greater than 20 with a broad confi-
dence interval (25, 95% CI 10.07 to ∞).
Episodes treated with parent initiated prednisolone
werelesslikelythanthosetreatedwithplacebotoresult
in substitution of the study medication with an oral
corticosteroid following a medical review (odds ratio
0.44, 95% CI 0.26 to 0.73; P=0.002). With regard to
episode severity (and thus the appropriateness of the
parent’s decision to initiate therapy), only 11 (7%) of
the 153 placebo treated episodes resolved within three
days, whereas 69 (45%) required health resource use
(local doctor, paediatrician, or emergency department
review). In 54 (78%) of these 69 cases, the study medi-
cation was substituted for a known oral corticosteroid.
There was no difference in the rate of behavioural
adverse effects between treatment groups.
The difference between treatment groups appeared
to be unrelated to the number of episodes contributed
by participants. Among participants who contributed
two or fewer episodes, treatment with prednisolone
was associated with an 18% reduction in the daytime
symptomscore(ratioofgeometricmeans0.82,95%CI
0.63 to 1.09) and an odds ratio for health resource use
of 0.53 (95% CI 0.25 to 1.10). In participants who
contributed more than two episodes, treatment with
prednisolone was associated with a 15% reduction in
153 episodes* (contributed by 65 participants)
treated with placebo
155 episodes* (contributed by 66 participants) 
treated with prednisolone
147 episodes* treated with
placebo as per protocol
147 episodes* treated with
prednisolone as per protocol
Children identified via the Geelong
Hospital during the course of the trial (n=27)
Children who met the eligibility
criteria (n=206)
Primary schools within the Barwon region: 91 schools (n=22 342 children)
Participating schools: 89 schools (n=21 762)
Parents who completed the asthma survey (n=16 977)
Parents who reported ≥4 episodes of wheeze during previous year (n=1279)
Parents who completed telephone interview (n=1215)
Children who met the telephone interview eligibility criteria (n=266)
Children who underwent paediatrician review (n=224)
Children randomised (n=230)
308 episodes* contributed by 131 participants
Children who consented (n=25) Children who consented (n=205)
Withdrew (n=2) 
Lost to follow-up (n=3)
No episodes* (n=94)
6 protocol violations** 8 protocol violations**
Fig 1 | Flowchart of recruitment, randomisation, and follow-up of participants and episodes
*Episodes=episodes of acute asthma for which the parent initiated treatment with the study
medication. **In each case the protocol violation consisted of ceasing the trial medication
early because symptoms had improved (without substitution for a known oral corticosteroid)
Table 2 |Baseline characteristics of participants who contributed episodes
All participants who contributed
episodes (n=131)
Participants who contributed
a single episode only (n=55)
Participants who
contributed more than
one episode (n=76) At enrolment At study completion Prednisolone (n=27) Placebo (n=28)
Age (mean (SD)) in years 7.9 (2.1) 10.6 (2.3) 8.0 (2.3) 7.7 (1.9) 7.9 (2.1)
Male sex 89 (69) — 20 (71) 20 (74) 49 (64)
Atopic sensitisation 94 (72) — 20 (74) 23 (82) 51 (67)
History of eczema 76 (58) — 16 (59) 18 (64) 42 (55)
Asthma interval symptoms 56 (43) 50 (38) 11 (41) 13 (46) 32 (42)
Prescribedregularuseofanasthmapreventive 89 (68) 59 (45) 19 (70) 22 (79) 48 (63)
Values are numbers (percentages) unless otherwise indicated.
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0.85, 95% CI 0.73 to 0.99) and an odds ratio for health
resource use of 0.55 (95% CI 0.31 to 1.00).
DISCUSSION
Principal findings of the study
This studyfound that, for childrenof school agewith a
history of frequent episodes of acute asthma, a short
course of oral prednisolone initiated by parents early
in the course of an episode of acute asthma was asso-
ciated with a modest reduction in asthma symptoms,
health resource use, and school absenteeism.
Several aspects of the methodology of this trial were
novel. For example, we used a single centre, popula-
tion based approach; by contrast, the vast majority of
largescaleinterventionaltrialsareundertakenatmulti-
ple centres. Although the multicentre approach facili-
tates recruitment, the single centre approach enabled
ustofosterasenseofcommunity“ownership”overthe
project,whichwasinvaluableindevelopingandmain-
taining participant involvement.
Our recruitment strategy was also novel. Our
approach of combing a population based survey of
asthmasymptoms
15andrequestingthatparentsvolun-
teer their contact details allowed us to efficiently iden-
tify and recruit approximately 60% of the relevant
children in the Barwon region. This survey also pro-
vided data on both the participants and their source
population,which assistedwith interpreting thegener-
alisability of the study findings. The strategy of ran-
domly allocating episodes of acute asthma rather than
participantswasalsoeffectivebecausethewithinparti-
cipant data reduced the diluting effect of between par-
ticipant variation in asthma phenotype, symptom
interpretation, and threshold for health resource use.
Comparison with other studies
Two previous randomised controlled trials found no
benefitassociatedwithparentinitiatedoralcorticoster-
oids.Thefirststudy,byGrantetal,
22evaluatedasingle
2mgperkgdoseofprednisoloneadministeredbypar-
entsattheonsetofwheezingin86childrenwithadiag-
nosis of “asthma.” The participants were aged 2 to
14 years, but most were less than 6 years of age. They
were observed for a 12 month period: during one six
month period the study medication was prednisolone,
during the other it was placebo. Surprisingly, the like-
lihoodofhealthresourceusewasgreaterduringthesix
monthswherethestudymedicationwasprednisolone.
There were no differences between treatment periods
in the other measured outcomes.
The second study, by Oommen et al,
9 evaluated in
childrenaged1to5yearstheefficacyof20mgpredni-
solone a day for five days administered by parents at
the onset of an episode of wheeze. A total of 217 chil-
dren were enrolled and data were collected on 121
wheeze episodes. There was no difference between
treatment groups in symptom scores, health resource
use, substitution of the study medication, or other out-
come measures.
Thereareseveralreasonswhyweobservedabenefit
from parent initiated oral corticosteroids whereas pre-
vious trials on parent led oral corticosteroid use have
not.
922 Most notably, the children included in this
study were of school age, whereas most of the partici-
pants in the previous trials on parent initiated oral cor-
ticosteroids were of preschool age.
922 There is good
evidence that oral corticosteroids are effective in
school age children with asthma,
2 whereas recent evi-
dence suggests that oral corticosteroids may not be
effectiveamongpreschoolchildrenwithvirusinduced
wheezing.
23
Table 3 |Symptom scores, asthma-free days, days of school missed by the participant, and
days of work missed by the parent
Number (%) of diaries
with relevant items
completed Mean (SD)
Ratio or difference*
(95% CI) P value
Daytime symptom score*
Prednisolone 140/155 (90) 1.19 (0.74) 0.85 (0.74 to 0.98) 0.023
Placebo 136/153 (89) 1.35 (0.67) ——
Night time symptom score*
Prednisolone 141/155 (91) −0.77 (1.00) 0.84 (0.7 to 1.0) 0.050
Placebo 137/153 (90) −0.54 (0.84) ——
Asthma-free days
Prednisolone 141/155 (91) 1.8 (1.8) 0.3 (−0.1 to 0.6) 0.124
Placebo 139/153 (91) 1.5 (1.7) ——
Days of school missed by the participant
Prednisolone 150/155 (97) 1.8 (1.9) −0.4 (−0.8 to 0.0) 0.045
Placebo 147/153 (96) 2.2 (2.2) ——
Days of work missed by the parent
Prednisolone 131/155 (85) 0.7 (1.4) −0.1 (−0.4 to 0.3) 0.765
Placebo 131/153 (86) 0.8 (1.4) ——
*Mean and standard deviation (SD) for daytime symptom scores and night time symptom scores were
calculated from natural log values, whereas the comparisons were back transformed to give geometric mean
ratios comparing prednisolone with placebo. To ensure non-negative values for log transformation, one half of
the minimum score (1/14=0.071) was added to the night time symptom scores before transformation.
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Total group (n=308)
Males (n=176)
Age 5-8 years (n=150)
Interval symptoms (n=133)
Prescribed an asthma preventive (n=155)
Atopic sensitisation (n=196)
Eczema (n=78)
Allergic rhinitis (n=88)
More competent parents (n=154) 0
0.5
1.0
1.5
DTSS
HRU
Fig 2 | Subgroup analysis of the effect of prednisolone
compared with placebo on daytime symptom score (DTSS)
and health resource use (HRU). n=number of episodes treated
with study medication where participants had the given
subgroup characteristic
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nistration of high doses of β agonists. The early effects
oforalcorticosteroidsarepartlyowingtoupregulation
of β receptors on the surface of airway smooth muscle,
rather than anti-inflammatory action.
2425 In the pre-
vious trials on parent initiated oral corticosteroids,
the recommended dose of β agonist was either lower
than that used in our trial (up to 400 μg of salbutamol)
9
or not specified.
22
Finally, our study had greater statistical power than
previous studies because we collected data on a higher
number of episodes and our data were paired.
Study limitations
Limitations to this study include not measuring the
severity of the episodes of acute asthma or the appro-
priateness of the parent’s decision to initiate the study
medication. We were unable to measure directly epi-
sode severity because of the study’s pragmatic design.
Our objective was to determine the effectiveness of a
healthcare strategy (parent initiated oral corticoster-
oids) rather than the efficacy of a therapeutic agent
(prednisolone).
Acrucialaspectofparentinitiationoforalcorticoster-
oidsisthat the parentmustmakethe decisiontoinitiate
treatmentwithouttheassistanceofahealthprofessional
to help evaluate episode severity. We judged that
attempting to measure objectively episode severity at
the time of oral corticosteroid initiation would under-
mine the study objective. It is possible that the effect of
prednisolone was diluted by the inclusion of data from
episodes where the parent initiated treatment without
an adequate indication. It should be noted, however,
that 69 (45%) of the 153 placebo treated episodes
resulted in health resource use. In 54 (78%) of these 69
instances, the study medication was substituted by the
treating doctor for a known oral corticosteroid, indicat-
ing that many of the episodes were not trivial.
We alsodidnotmeasure theparticipants’lungfunc-
tion. Paediatric lung function testing is not available to
most general practitioners. Given that parent initiated
use of oral corticosteroids is a strategy that is particu-
larly relevant to general practitioners, it was our view
that the study eligibility criteria should reflect para-
meters that might be readily applied in the general
practice setting.
Conclusions and policy implications
Theresultsofthisstudyareimportantbecausetherehas
been minimal previous success in identifying parent
initiated strategies that may reduce the burden of acute
asthmainchildren.Oneoftheapproachesthathasbeen
evaluated is administration of a short course of inhaled
corticosteroids. Although there is some evidence that
high dose inhaled corticosteroids may be effective in
the treatment of acute asthma in the hospital setting
26
and may also be associated with modest benefit in the
ambulatory setting,
27 high dose inhaled corticosteroids
are not as effective as oral corticosteroids.
28
Asecondapproachistheuseofformulationscontain-
inganinhaledcorticosteroidandalongactingβagonist.
Among children with uncontrolled asthma, the use of
inhaled corticosteroids and a long acting β agonist as
both maintenance and reliever medication may reduce
asthmarelatedhealthresourceusecomparedwithfixed
dose inhaled corticosteroids and a long acting β agonist
as maintenance treatment only.
29 However, fewer than
15% of children who present to an emergency depart-
ment with an episode of acute asthma have a
background of uncontrolled asthma
30; therefore, main-
tenanceandrelievertreatmentwithinhaledcorticoster-
oidsandalongactingβagonistisnotappropriateforthe
great majority of children likely to use health resources
to relieve acute asthma.
A third option is the use of a short course of the leu-
kotrienereceptorantagonistmontelukast.Thereisevi-
dence that parent initiated montelukast in children of
preschool age with intermittent asthma is associated
with a reduction in asthma symptoms and health
resource use.
31 The magnitude of benefit is similar to
that seen with parent initiated oral corticosteroids in
this study. The evidence regarding short course mon-
telukast in the treatment of acute asthma in school age
childrenisinadequate,however,andtherearenohead
toheadtrialscomparingshortcoursemontelukastwith
oral corticosteroids for acute asthma in any age group.
What,then,istheroleofparentinitiatedoralcorticos-
teroids in the management of childhood asthma? From
a health resource viewpoint, the use of parent initiated
oral corticosteroids is cheap and seems tobe associated
with an important reduction in health resource use,
which is costly.Fromthe patient’s viewpoint, however,
the symptom benefit is modest, and a relatively large
Table 4 |Health resource use and study medication substitution
Outcome
Prednisolone
(n=155 )
Placebo
(n=153)
Odds ratio
(95% CI) P value
Number of episodes
needed to treat (95% CI)
Local doctor review* 36/155 (23%) 53/153 (35%) 0.57 (0.35 to 0.92) 0.022 8.3 (4.5 to 50.0)
Emergency department review* 15/155 (10%) 21/153 (14%) 0.67 (0.33 to 1.34) 0.254 25 (9.1 to ∞)
Hospital admission* 6/155 (4%) 12/153 (8%) 0.41 (0.16 to 1.05) 0.064 25 (10.7 to ∞)
Health resource use† 48/155 (31%) 69/153 (45%) 0.54 (0.34 to 0.86) 0.010 7.1 (4.0 to 30.3)
Study medication substitution
Study medication changed to an oral corticosteroid following a medical review 30/155 (19%) 54/153 (35%) 0.44 (0.26 to 0.73) 0.002 6.2 (3.9 to 16.1)
Study medication changed to an oral corticosteroid because episode resulted
in health resource use
30/48 (63%) 54/69 (78%) 0.44 (0.21 to 0.95) 0.047 —
*Local doctor review, emergency department review, and hospital admission are not reported as mutually exclusive outcomes.
†Health resource use comprises local doctor, paediatrician, or emergency department review.
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the need for a medical review or hospital admission. In
addition, the detrimental effects of recurrent short
courses of oral corticosteroids may be significant.
5-8 It
seems sensible that if a child of school age has experi-
encedrepeatedepisodesofacuteasthmathatresultedin
health resource use, the parent should be advised to
keep oral corticosteroids available to be used in the
event of a relatively severe episode. The clinician
should, however, regularly review the frequency and
appropriateness of parent initiated oral corticosteroids
and health resource use to minimise the risk of adverse
events related to the oral corticosteroids.
In summary,we found that in children of school age
withahistoryofrecurrentacuteasthma,ashortcourse
ofparentinitiatedoralprednisolonecommencedearly
inthecourseofanepisodeofacuteasthmaisassociated
with a modest reduction in asthma related symptoms,
health resource use, and school absenteeism. Parent
initiated prednisolone may be an appropriate strategy
for the management of more severe episodes of acute
asthmainchildrenofschoolage.However,themodest
benefits of this strategy must be balanced against
potentialsideeffectsofrepeatedcoursesofanoralcor-
ticosteroid.
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